Trials / Recruiting
RecruitingNCT07152236
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
A Clinical Study Evaluating the Safety and Efficacy of B7H3 CAR-T Cell Therapy in Patients With B7H3-Positive Solid Tumors
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd · Industry
- Sex
- All
- Age
- 1 Year – 75 Years
- Healthy volunteers
- Not accepted
Summary
This single-arm, single-center investigator-initiated trial (IIT) evaluates the safety, efficacy, and pharmacodynamic (PD)/pharmacokinetic (PK) profiles of CAR-T cells in patients with advanced solid tumors. Eligible subjects are followed until 12 months after infusion or until meeting treatment withdrawal criteria, whichever occurs first.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-T | Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy. |
Timeline
- Start date
- 2025-08-31
- Primary completion
- 2028-08-31
- Completion
- 2028-08-31
- First posted
- 2025-09-03
- Last updated
- 2025-09-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07152236. Inclusion in this directory is not an endorsement.